Current status

Our In-vitro studies have identified three saponin-based formulations and have demonstrated efficacy against solid and non-solid cancer tumors

  • 2017, CRODA International PLC acquired part of the patent portfolio covering the use of adjuvants for Vaccine applications.
  • CRODA International PLC has manufacturing rights to the product in question.
  • These types of particles (ISCOM) have been commercialized in Novavax Inc.´s Covid vaccine, NVX-CoV2373.

Our In-vitro studies have identified three saponin-based formulations and have demonstrated efficacy against solid and non-solid cancer tumors